CureGene Enthralls with Innovative CG-0416 for Obesity Treatment at Obesity Week 2025 CureGene Pharmaceuticals presents exciting preclinical data on CG-0416, a transformative oral weight-loss therapy, aimed at revolutionizing obesity treatments.

CureGene Enthralls with Innovative CG-0416 for Obesity Treatment at Obesity Week 2025 #China #Shanghai #CureGene #Obesity_Treatment #CG-0416

Groundbreaking Dual-Action Therapy CG-0416 Revolutionizes Obesity Management at 2025 EASL Congress At the 2025 EASL Congress, CureGene Pharmaceuticals revealed CG-0416, a pioneering dual-action therapy targeting obesity and liver health with remarkable efficacy.

Groundbreaking Dual-Action Therapy CG-0416 Revolutionizes Obesity Management at 2025 EASL Congress #China #Shanghai #CureGene #EASL_Congress #CG-0416

CureGene's New Antiplatelet Therapy CG-0255 Gains Clinical Trial Approval in China CureGene has announced the approval of its innovative antiplatelet drug CG-0255 for clinical trials in China, targeting coronary artery disease.

CureGene's New Antiplatelet Therapy CG-0255 Gains Clinical Trial Approval in China #China #Shanghai #CureGene #CAD #CG-0255